Faced with mounting legal costs related to its transvaginal mesh device, Boston Scientific (NYSE: BSX) (Marlborough, Mass.) slashed its full-year profit forecast for the second time this year. Boston Scientific cut its profit forecast by 4 cents to 28-34 cents a share on Thursday, but maintained its adjusted profit forecast. Read More
